drugset / Trial / NCT02462707
A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
Parallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended Phase 2 dose for PF-03084014 single-agent administration in Japanese patients with advanced solid tumors. Pharmacokinetics and the overall safety profile of PF-03084014 will also be evaluated.
Timeline
- Start
- 2015-07
- Primary completion
- 2016-06
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirogacestat | Small molecule | 80 mg | Oral |
| Subject | Nirogacestat | Small molecule | 100 mg | Oral |
| Subject | Nirogacestat | Small molecule | 150 mg | Oral |